Severe combined immunodeficiency

Showing all 5 results

  • Severe combined immunodeficiency

    Human gamma globulin

    【Product name】Human γ-globulin

    [English common name]Human Normal Immunoglobulin

    [Chinese common name]Human gamma globulin

    [English name]

    [Chinese other name] Γ-human globulin

    [indications]
    1. Mainly used to prevent measles or relieve symptoms.
    2. For the prevention and treatment of viral infections such as infectious hepatitis, measles, chickenpox, mumps and herpes zoster.
    3. forasthmaEndogenous allergic diseases such as allergic rhinitis and eczema.
    4. Used to improve the body's immune function:
    (1) Primary immunoglobulin deficiency, common variant immunodeficiency disease, immunoglobulin G subtype deficiency disease, etc.
    (2) secondary immunoglobulin deficiency diseases, such as severe infection, neonatal sepsis.
    (3) autoimmune diseases such as primaryThrombocytopeniaAster, Kawasaki disease.

    【Dosage】
    Primary thrombocytopenic purpura: 400mg/kg daily for 5 consecutive days, maintenance dose: 200 ~ 400mg / kg each time, the interval of administration depends on the condition, usually once a week. Severe infection: 200 ~ 300mg / kg per day, for 2 to 3 days. Usage: intravenous drip or diluted 5% glucose injection 1 to 2 times after intravenous infusion, the initial drip rate is 1.0ml / min, no adverse reactions after 15 minutes can speed up the drip rate, the fastest can not exceed 3.0ml / minute.

    [Storage]seal.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Ataxia - telangiectasia , Severe combined immunodeficiency

    Thymosin

    【Product name】ZADAXIN, THYMIN(RG)

    [English common name]Thymosin

    [Chinese common name]Thymosin

    [English name]Thymin

    [Chinese other name]Thymosin

    [indications]
    Chronic hepatitis B 
    This product is used to treat patients with chronic hepatitis B over the age of 18, and the patient's liver disease is compensatory and has hepatitis B virus replication (serum HBV-DNA positive), in those serum hepatitis B surface antigen (HBsAg) positive Studies in patients with a minimum of 6 months and elevated serum aminotransferase (ALT) have shown that treatment with this product can produce viral remission (serum HBV-DNA loss) and retransferase levels. In some responding patients, the drug treatment removes serum surface antigens. Clinical trials suggest that when this drug is combined with alpha interferon, it may have a higher response rate than the drug alone or with interferon alone.
    An immunopotentiator for immunocompromised patients 
    The immune system is inhibited, including those who receive chronic hemodialysis and elderly patients. This medicine can enhance the immune response of patients to viral vaccines such as influenza vaccine or hepatitis B vaccine. Studies on hemodialysis patients have shown that 65% of patients who took this drug as an adjuvant had an anti-influenza antibody titer level that increased more than four-fold after flu vaccine, and only 24% of patients in the placebo group responded.

    【Dosage】
    This product should not be used for intramuscular or intravenous injection. It should be subcutaneously injected immediately after dissolution with 1.0 ml of water for injection in the box. Dosages can be used as directed by your doctor.
    Chronic hepatitis B This product is recommended for the treatment of chronic hepatitis B. The subcutaneous injection of 1.6 mg per needle is twice a week, and the two doses are approximately 3-4 days apart. Treatment should be uninterrupted for 6 months (52 needles).
    If this product is used in combination with alpha interferon, the dose and precautions in the alpha interferon prescription data should be consulted. In a combined clinical trial, when the two drugs are used on the same day, the product is usually administered in the morning and the interferon is administered at night.
    As a vaccine booster for immunocompromised patients, this product is used as a viral vaccine enhancer. The recommended dose is 1.6mg subcutaneous injection, twice a week, 3 to 4 days apart, and the course of treatment should last 4 weeks (8 needles in total). The first needle should be given immediately after vaccination.
    The physician decides whether to teach the patient to self-inject.

    [Storage]Sealed, shading, stored at 2-8 ° C (36 ° ~ 46 ° F), immediately after preparation.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Severe combined immunodeficiency

    Adenosine deaminase (ADA)

    【Product name】Strimvelis, Adenosine Deaminase Antibody

    [English common name]Adenosine Deaminase

    [Chinese common name]Adenosine deaminase (ADA)

    [English name]ADA

    [Chinese other name]Adenine deaminase

    [indications]Strimvelis is available for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA), a relevant stem cell donor who does not have a suitable human leukocyte antigen (HLA) match.

    【Dosage】
    Strimvelis must be performed by a professional transplant center, with ADA-SCID patient treatment and management experience and with a physician using autologous CD34 + ex vivo gene therapy products. Strimvelis should only be performed after consultation with patients and/or family members. Patients are expected to enter the post-treatment registry and will be followed for long-term follow-up.
    CD34+ stem cells containing at least 1 million CD34+ cells per kilogram are required for use. This should be harvested from the patient at least 3 weeks prior to treatment with Strimvelis. If the product is manufactured after treatment with Strimvelis, failure occurs during transplantation or long-term bone marrow dysplasia, the stem cells are collected for use as salvage therapy.
    Patients must be able to donate enough CD34+ cells to provide the minimum of 4 million purified CD34+ cells/kg required to make Strimvelis.
    Strimvelis is for self-use only. Prior to infusion, the patient's identity must be confirmed to match the basic unique patient information on the Strimvelis infusion bag and/or container.

    [Storage] shelf life of 6 hours, must be stored inAt 15-30 ° C.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Severe combined immunodeficiency

    Hyaluronidase

    【Product name】Rituxan, Amphadase, Hylenex, Vitrase

    [English common name]Hyaluronidase

    [Chinese common name]Hyaluronidase

    [English name]Chondroitinase, Hyaluronoglucosidase, Neopermease

    [Chinese other name]Sheep testis, hyaluronidase IS, hyaluronidase (goat testis)

    [indications] forImmunodeficiencyPediatric patients.

    【Usage and Dosage】 Pediatric medication
    Hyaluronidase can be added to small volumes of solution (up to 200 mL), such as for small assays for infants or for drug solutions for subcutaneous injection. The possibility of chemical or physical incompatibility should be kept in mind. For infants and children under 3 years of age, the volume of a single infusion should be limited to 200 mL; during preterm or neonatal periods, the daily dose should not exceed 25 mL / kg body weight; the rate of administration should not exceed 2 ml per minute . For older patients, the rate and volume of administration should not exceed the amount of intravenous infusion.

    [Storage]Sealed, cool, dry and stored.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Severe combined immunodeficiency

    Aldileukin (interleukin-2)

    【Product name】Proleukin

    [English common name]Proleukin

    [Chinese common name]Aldileukin

    [English name]Aldesleukin

    [Chinese other name]

    [Indications] Proleukin® (aldesleukin) is suitable for the treatment of metastasisRenal cell carcinomaAdults with metastatic (transferable RCC)MelanomaAdult.

    【Dosage】
    1. Usage of IL-2: IL-2 dosage is used according to clinical needs and under the guidance of experienced physicians.
    (1) Subcutaneous injection: IL-2, 200,000 to 400,000 U/m2 is dissolved in 2 ml of sterile water for injection, once a day for 4 days, 4 weeks for 1 course.
    (2) intravenous drip: IL-2, 200,000 ~ 400,000 U / m2, 500ml of normal saline, intravenous infusion of 2 ~ 3h, once a day, 4 days a week, for 4 weeks for a course of treatment.
    (3) intraluminal perfusion: first drain the intracavitary effusion or intubation drainage, and then inject IL-2.4 million ~ 500,000 U / m2 into physiological saline 20ml, 1 or 2 times a week, every 3 to 4 weeks For a course of treatment, such as the disappearance of fluid in the course of treatment, it is advisable to stop treatment.
    (4) intratumoral or peritumoral injection: IL-2, 100,000 to 300,000 U, adding 3 to 5 ml of normal saline, and injecting multiple points into the tumor or around the tumor, 2 times or more per week, for continuous use 2 weeks is a course of treatment. 2. Usage of IL-2 LAK cells: The dose and usage of IL-2 are the same as the intravenous or subcutaneous routes of administration of IL-2 described above. After receiving intravenous or subcutaneous injection of IL-2 for 2 days, autologous LAK was prepared by intravenous blood sampling and returned to the patient. The average number of LAK cells returned to the whole course was 1.2×109; the autologous preparation of blood lymphocytes was separated by blood cell separator. LAK, the average number of LAK cell transfusions in the whole course of treatment was 5.4×109; in some cases, allogeneic LAK cells were returned, and the average LAK cell return was 6.1×109. 3. 25-50 μg/kg per day, injected with 1 ml. Dissolve in water, subcutaneously, for 7 to 14 days. The number of peripheral blood platelets was measured during the administration, and the platelets should be discontinued when they recovered to 100×109/L or more.

    [Storage]The preparation should be stored at 2-8 °C.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.